ReShape Lifesciences (RSLS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update Revenue totaled $1.9 million for the three months ended March 31, 2024, which represents a contraction of 15.0$0.3 million compared to the same period in 2023. The primary reason is due to a decrease in sales volume primarily due to GLP-1 pharmaceuticals. Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% ...